vs
Side-by-side financial comparison of Gitlab Inc. (GTLB) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $244.4M, roughly 1.2× Gitlab Inc.). Bio-Techne runs the higher net margin — 12.8% vs -3.4%, a 16.2% gap on every dollar of revenue. On growth, Gitlab Inc. posted the faster year-over-year revenue change (24.6% vs -6.4%). Over the past eight quarters, Gitlab Inc.'s revenue compounded faster (22.1% CAGR vs 4.2%).
GitLab Inc. is an American company that operates and develops GitLab, an open-core DevOps software package that can develop, secure, and operate software. GitLab includes a distributed version control system based on Git, including features such as access control, bug tracking, software feature requests, task management, and wikis for every project, as well as snippets.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
GTLB vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $244.4M | $295.9M |
| Net Profit | $-8.3M | $38.0M |
| Gross Margin | 86.8% | 64.6% |
| Operating Margin | -5.1% | 18.4% |
| Net Margin | -3.4% | 12.8% |
| Revenue YoY | 24.6% | -6.4% |
| Net Profit YoY | -128.0% | 68.3% |
| EPS (diluted) | $-0.05 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $244.4M | $295.9M | ||
| Q3 25 | $236.0M | — | ||
| Q2 25 | $214.5M | $317.0M | ||
| Q1 25 | $211.4M | $316.2M | ||
| Q4 24 | $196.0M | $297.0M | ||
| Q3 24 | $182.6M | $289.5M | ||
| Q2 24 | $169.2M | $306.1M | ||
| Q1 24 | $163.8M | $303.4M |
| Q4 25 | $-8.3M | $38.0M | ||
| Q3 25 | $-9.2M | — | ||
| Q2 25 | $-35.9M | $-17.7M | ||
| Q1 25 | $5.8M | $22.6M | ||
| Q4 24 | $29.6M | $34.9M | ||
| Q3 24 | $12.9M | $33.6M | ||
| Q2 24 | $-54.6M | $40.6M | ||
| Q1 24 | $-36.5M | $49.1M |
| Q4 25 | 86.8% | 64.6% | ||
| Q3 25 | 87.9% | — | ||
| Q2 25 | 88.3% | 62.7% | ||
| Q1 25 | 89.2% | 67.9% | ||
| Q4 24 | 88.7% | 65.3% | ||
| Q3 24 | 88.3% | 63.2% | ||
| Q2 24 | 88.9% | 66.4% | ||
| Q1 24 | 90.2% | 67.4% |
| Q4 25 | -5.1% | 18.4% | ||
| Q3 25 | -7.8% | — | ||
| Q2 25 | -16.1% | -7.5% | ||
| Q1 25 | -9.1% | 12.2% | ||
| Q4 24 | -14.7% | 16.0% | ||
| Q3 24 | -22.5% | 13.8% | ||
| Q2 24 | -31.7% | 15.0% | ||
| Q1 24 | -21.3% | 22.1% |
| Q4 25 | -3.4% | 12.8% | ||
| Q3 25 | -3.9% | — | ||
| Q2 25 | -16.7% | -5.6% | ||
| Q1 25 | 2.7% | 7.1% | ||
| Q4 24 | 15.1% | 11.7% | ||
| Q3 24 | 7.1% | 11.6% | ||
| Q2 24 | -32.3% | 13.3% | ||
| Q1 24 | -22.3% | 16.2% |
| Q4 25 | $-0.05 | $0.24 | ||
| Q3 25 | $-0.06 | — | ||
| Q2 25 | $-0.22 | $-0.11 | ||
| Q1 25 | $0.05 | $0.14 | ||
| Q4 24 | $0.18 | $0.22 | ||
| Q3 24 | $0.08 | $0.21 | ||
| Q2 24 | $-0.35 | $0.26 | ||
| Q1 24 | $-0.23 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $224.2M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $922.7M | $2.0B |
| Total Assets | $1.6B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $224.2M | $172.9M | ||
| Q3 25 | $261.4M | — | ||
| Q2 25 | $255.7M | $162.2M | ||
| Q1 25 | $227.6M | $140.7M | ||
| Q4 24 | $176.6M | $177.5M | ||
| Q3 24 | $438.6M | $187.5M | ||
| Q2 24 | $420.3M | $152.9M | ||
| Q1 24 | $288.0M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $922.7M | $2.0B | ||
| Q3 25 | $866.6M | — | ||
| Q2 25 | $808.3M | $1.9B | ||
| Q1 25 | $775.9M | $2.0B | ||
| Q4 24 | $724.7M | $2.1B | ||
| Q3 24 | $642.8M | $2.1B | ||
| Q2 24 | $567.8M | $2.1B | ||
| Q1 24 | $571.2M | $2.0B |
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.4B | $2.6B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.3B | $2.7B | ||
| Q3 24 | $1.4B | $2.7B | ||
| Q2 24 | $1.3B | $2.7B | ||
| Q1 24 | $1.3B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.4M | — |
| Free Cash FlowOCF − Capex | $28.4M | — |
| FCF MarginFCF / Revenue | 11.6% | — |
| Capex IntensityCapex / Revenue | 1.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $242.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.4M | — | ||
| Q3 25 | $49.4M | — | ||
| Q2 25 | $106.3M | $98.2M | ||
| Q1 25 | $63.2M | $41.1M | ||
| Q4 24 | $-177.0M | $84.3M | ||
| Q3 24 | $11.7M | $63.9M | ||
| Q2 24 | $38.1M | $75.5M | ||
| Q1 24 | $24.9M | $81.0M |
| Q4 25 | $28.4M | — | ||
| Q3 25 | $46.5M | — | ||
| Q2 25 | $105.4M | $93.3M | ||
| Q1 25 | $62.1M | $31.0M | ||
| Q4 24 | $-178.1M | $77.5M | ||
| Q3 24 | $10.8M | $54.7M | ||
| Q2 24 | $37.4M | $57.5M | ||
| Q1 24 | $24.5M | $64.5M |
| Q4 25 | 11.6% | — | ||
| Q3 25 | 19.7% | — | ||
| Q2 25 | 49.1% | 29.4% | ||
| Q1 25 | 29.4% | 9.8% | ||
| Q4 24 | -90.8% | 26.1% | ||
| Q3 24 | 5.9% | 18.9% | ||
| Q2 24 | 22.1% | 18.8% | ||
| Q1 24 | 15.0% | 21.3% |
| Q4 25 | 1.2% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.5% | 3.2% | ||
| Q4 24 | 0.5% | 2.3% | ||
| Q3 24 | 0.5% | 3.2% | ||
| Q2 24 | 0.4% | 5.9% | ||
| Q1 24 | 0.2% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 10.89× | 1.82× | ||
| Q4 24 | -5.99× | 2.42× | ||
| Q3 24 | 0.90× | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GTLB
| Subscription And Circulation | $146.4M | 60% |
| Subscription Software As A Service | $76.9M | 31% |
| License | $15.5M | 6% |
| Professional Services And Other | $5.6M | 2% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
